- Home
- GENK vs INTS Comparison
GENK vs INTS Comparison
Compare GENK & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- INTS
- Stock Information
- Founded
- GENK 2011
- INTS 2012
- Country
- GENK United States
- INTS United States
- Employees
- GENK N/A
- INTS N/A
- Industry
- GENK Restaurants
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- GENK Consumer Discretionary
- INTS Health Care
- Exchange
- GENK Nasdaq
- INTS Nasdaq
- Market Cap
- GENK 36.5M
- INTS 33.4M
- IPO Year
- GENK 2023
- INTS 2023
- Fundamental
- Price
- GENK $5.51
- INTS $2.23
- Analyst Decision
- GENK Strong Buy
- INTS Strong Buy
- Analyst Count
- GENK 3
- INTS 3
- Target Price
- GENK $13.17
- INTS $8.50
- AVG Volume (30 Days)
- GENK 63.0K
- INTS 24.9K
- Earning Date
- GENK 03-05-2025
- INTS 03-13-2025
- Dividend Yield
- GENK N/A
- INTS N/A
- EPS Growth
- GENK 483.78
- INTS N/A
- EPS
- GENK 0.17
- INTS N/A
- Revenue
- GENK $198,834,000.00
- INTS N/A
- Revenue This Year
- GENK $14.66
- INTS N/A
- Revenue Next Year
- GENK $21.47
- INTS N/A
- P/E Ratio
- GENK $33.95
- INTS N/A
- Revenue Growth
- GENK 12.50
- INTS N/A
- 52 Week Low
- GENK $5.26
- INTS $1.50
- 52 Week High
- GENK $14.46
- INTS $5.94
- Technical
- Relative Strength Index (RSI)
- GENK 31.30
- INTS 49.26
- Support Level
- GENK $5.26
- INTS $1.84
- Resistance Level
- GENK $5.73
- INTS $2.27
- Average True Range (ATR)
- GENK 0.35
- INTS 0.28
- MACD
- GENK 0.01
- INTS -0.01
- Stochastic Oscillator
- GENK 18.52
- INTS 56.36
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc is an Asian casual dining restaurant in the United States. It offers an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.